Dilmapimod

• UNSPSC Description:

  Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.

• Target Antigen:

  Autophagy; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy;MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/SB-681323.html

• Purity:

  99.56

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C1C=CC2=C(C3=CC=C(F)C=C3C)N=C(NC(CO)CO)N=C2N1C4=C(F)C=CC=C4F

• Molecular Weight:

  456.42

• References & Citations:

  [1]Singh D, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010 Jan;50(1):94-100.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  444606-18-2